FOXO4-DRI is a protease-resistant D-retro-inverso cell-penetrating peptide engineered to disrupt the nuclear FOXO4–p53 interaction, selectively triggering p53-mediated apoptosis in senescent cell models.
Scientific Profile & Research Key Points: FOXO4-DRI
FOXO4-DRI is a protease-resistant D-retro-inverso cell-penetrating peptide engineered to disrupt the nuclear FOXO4–p53 interaction, selectively triggering p53-mediated apoptosis in senescent cell models.
Active Batch Release Specifications (Lot SL-2026-123)
Analytical release verification for current FOXO4-DRI (10 mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-123 | 2026-10-28 | RP-HPLC (C18, 214nm) + ESI-MS | ≥99.0% (Single Peak) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile PBS (pH 7.4) or sterile 0.9% Bacteriostatic Water
Temperature & Stability
Store lyophilized at -20°C; protect from prolonged UV exposure due to D-Trp residue.
FOXO4-DRI — Technical Questions & Answers
What is the molar concentration when reconstituting FOXO4-DRI (10 mg) in 2.0 mL?
Reconstituting the full 10 mg vial of FOXO4-DRI (MW 5358.13 g/mol) in 2.0 mL of diluent produces a 5.00 mg/mL stock solution — equivalent to approximately 0.93 mM (933 µM) gross molarity before Net Peptide Content (NPC) adjustment.
How does FOXO4-DRI's counterion stoichiometry affect assay mass calculations?
FOXO4-DRI (CAS 2460055-10-9, formula C228H388N86O64) is supplied as Acetate lyophilized salt. Because counterions and residual bound water contribute to gross lyophilized weight, quantitative receptor-binding assays should apply batch Net Peptide Content (NPC) or active-ion correction rather than gross cake weight alone.
Which analytical methods verify FOXO4-DRI Lot SL-2026-123 and what pathway does it target?
Lot SL-2026-123 undergoes RP-HPLC (C18, 214nm) + ESI-MS confirming ≥99.0% (Single Peak) and identity against 5358.13 g/mol. In preclinical literature, FOXO4-DRI targets FOXO4–p53 protein–protein interaction (senolytic pathway) (Baar M.P. et al., Cell (2017) — Targeted apoptosis of senescent cells via FOXO4–p53 interference (PMID: 28340339)).
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
SLU-PP-332: Synthetic Pan-ERR Agonist Chemistry, DMSO Solubility & Mitochondrial Biogenesis
Analytical profile of small-molecule pan-ERR agonist SLU-PP-332 (CAS 303760-60-3): nuclear receptor EC50 selectivity, mitochondrial respiration models, and DMSO stock preparation.
GHK-Cu: Biochemistry of the Gly-His-Lys Copper Complex in Gene Expression and Tissue Remodeling
A biochemical review of the human tripeptide copper complex GHK-Cu. Epigenetic gene resetting, metalloproteinase modulation, collagen/elastin synthesis, and analytical HPLC verification.
Glutathione: The γ-Glutamyl Isopeptide Bond, Redox Potentials, and GSSG Dimerization
A molecular analysis of reduced Glutathione (GSH) vs oxidized Glutathione Disulfide (GSSG). Why the unusual gamma-peptide bond protects against intracellular peptidases.
Related Longevity & Cellular Biology Compounds
View category →